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A significant new innovation-development model is being launched in the field of can-
cer and nanotechnology. Here at Springer’s Cancer Nanotechnology office, we thought 
it would be something of interest to our readers. Known as the Nano Startup Challenge 
in Cancer—or NSC2 for short—this exciting model is being run by the National Cancer 
Institute (NCI) in partnership with the Centre for Advancing Innovation and is being 
supported by MedImmune/AstraZenica. This article is the first in a set covering the 
challenge as it unfolds.
Following two award-winning competitions (the Breast Cancer Startup Challenge and 
the Neuro Startup Challenge) NSC2, the third in the series of challenges, is structured 
as an open innovation competition designed to bring promising nanotechnology cancer 
inventions to market.
Pivotal to the NSC2 challenge is a new business model: instead of potential costs of 
$2–5 M to secure an exclusive license leading to commercialization, a new startup exclu-
sive license agreement may allow newly generated companies greater chances to bring 
inventions to market. Constructed by the National Institute of Health, the new license 
agreement will be the basis upon which the winning startups in the challenge go forward 
with upfront cost of only $2000 for an exclusive license agreement—details can be found 
at http://www.ott.nih.gov/nih-start-exclusive-license-agreements.
All of these inventions are concerned with nanotechnology as applied to cancer and 
all have the potential to make a significant therapeutic impact on the health of cancer 
patients.
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In a notable difference from the two previous challenges, NSC2 inventions can origi-
nate from either the NIH intramural research program or the extramural research 
community. Entrants register via the website (http://www.nscsquared.org) and then self-
assemble into teams which compete to take forward one of the inventions. Entry is open 
to anyone, anywhere in the world, provided they are over 18 years of age. The resulting 
multidisciplinary teams are required to have expertise in business, medicine, science and 
law. Each team will contain at least one serial entrepreneur and two students. The teams 
will interact with a panel of internationally renowned judges/mentors including heads of 
venture for large companies active in this sector.
As part of our coverage, we at Cancer Nanotechnology journal are going to offer teams 
the chance to write a scientific article about the invention they are progressing.
We interviewed Rosemary Truman, CEO for the Centre of Advancing Innovation, and 
Piotr Grodzinski, Director of National Cancer Institute Alliance for Nanotechnology 
in Cancer at the National Cancer Institute in Bethesda, to learn a bit more about the 
startup challenge model in general and this specific competition.
When asked about the value of engaging with the scientific community in this way, 
Rosemary Truman said that the teams would benefit from: “constructive feedback and 
exposure to people who think about it differently than they do. It may change their whole 
approach to commercialisation”. She sees the feedback and suggestions/guidance of the 
world-class industry and academic mentors and advisors as being immensely valuable 
as it draws from: “a large network of people thinking about the same kinds of problems.” 
In addition, the teams coming into the challenge are multidisciplinary and this allows 
scientists to engage with crucial talent that drive successful commercialization. Finally, 
the accelerator provides 40 classes that provide scientists an opportunity to learn the 
“business of science.”
Piotr Grodzinski was keen to emphasize the developmental and educational aspects 
of the process for those involved. He views the articles in Cancer Nanotechnology as an 
opportunity for teams to indicate: “why they think it can result in a practical clinical 
solution long term.” He also pointed out that the new paradigm could result in a new 
way of thinking for researchers, something he summarized with the pithy phrase: “Their 
sandbox becomes bigger.”
Of course, we will be watching and reporting on developments as the NSC2 challenge 
proceeds, as well as publishing the papers arising. If you feel you would like to enter the 
competition, it still is not too late; you have until 14th March—entry instructions along 
with other details are all available at http://www.nscsquared.org.
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